Abstract：ObjectiveTo explore the effect of Recombinant Human Brain Natriuretic Peptide treating acute decompensated heart failure.Methods100 patients with acute decompensated heart failure treated in our hospital from May 2015 to May 2016 were selected and they were divided into the two groups using the lottery method,and there were 50 patients in each group.The control group and observation group was treated by Isosorbide Mononitrate and Recombinant Human Brain Natriuretic Peptide.6-minute walking distance,24-hour urine output,respiratory rate,heart rate and the cardiac function indexes were compared between the two groups.Results6-minute walking distance[(114.69±6.89)m],24-hour urine output[(2458.32±68.58)ml],respiratory rate[(18.65±1.54)times/min],heart rate[(74.56±2.65)times/min],LVEDD [(60.96±2.02)mm],LVESD[(46.36±1.38)mm],LVEF[(46.36±1.38)%]were better than those of control group [(85.43± 5.32)m,(1453.28±11.58)ml,(24.31±1.05)times/min,(84.62±3.44)times/min,(65.54±1.83)mm,(55.68±1.62)mm,(43.46± 1.84)%](P＜0.05).ConclusionThe effect of Recombinant Human Brain Natriuretic Peptide treating acute decompensated heart failure is significant.
Tschierschke R，Katus HA，Raake PW，et al.First"advanced Heart Failure Unit"at the heart centre of the university hospital Heidelberg：example for integrated care structures for optimized treatment of terminal heart failure[J].DMW，2013，138（12）：603-606.
京公网安备 11010502046607号